Antacid medications as anticancer agents improve patients survival and clinical outcome
We have solid evidence which demonstrate that patients with head neck squamous cell carcinomas (HNSCC) might benefit from antacids medications as part of their cancer treatment at the UM. Our retrospective molecular epidemiological study is the first to unveil a significant survival benefit of antacids in HNSCC patients (Figure). An innovative project is proposed: 1) to confirm associations of patient outcome with clinical use of antacids in a large HNSCC patients database (over 66,000.00); and 2) to explore the mechanisms of action by which antacids might protect against cancer progression by pathway modulation and disease outcome. The combination of an epidemiological study with mechanistic studies provides synergistic significance and comprehensive support for a novel therapeutic approach in HNSCC that could be readily translated into clinical benefit to any cancer patient.